Pharma Business International

1 month ago | pbiforum.net | Tess Egginton

The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The decision was based on the potential of the vaccine candidate to address a serious condition and address an unmet public health need. The chlamydia vaccine candidate has been designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis.

1 month ago | pbiforum.net | Tess Egginton

Augustine Therapeutics, a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, has completed its Series A financing round raising a total of €77.7 million.

1 month ago | pbiforum.net | Tess Egginton

Mallinckrodt and Endo have entered into a definitive agreement to combine in a $6.7 billion deal, Under the terms of the agreement, Endo shareholders will receive a total of $80 million in cash and will own 49.9% of the combined company. Mallinckrodt shareholders will own 50.1% of the combined company. Mallinckrodt will continue as the holding company for the combined business, and Endo will become a wholly-owned subsidiary of Mallinckrodt.

1 month ago | pbiforum.net | Tess Egginton

Ono Pharmaceutical has entered into a license agreement with Ionis Pharmaceuticals for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Sapablursen is currently being evaluated in adult patients with PV in the fully enrolled Phase 2 IMPRSSION study. Sapablursen was granted Fast Track designation in January 2024 and orphan drug designation in August 2024 by the U.S. Food and Drug Administration (FDA).

1 month ago | pbiforum.net | Tess Egginton

ONCOVITA, a biotechnology company specializing in innovative vaccine development and a spin-off from the Institut Pasteur, and UNITHER Pharmaceuticals, a global leader in sterile unit-dose manufacturing, have formed a strategic partnership to develop and produce a new combined prophylactic vaccine for the prevention of infectious diseases in children.